BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$61.93 USD
+1.62 (2.69%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $61.92 -0.01 (-0.02%) 5:28 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, BioMarin Pharmaceutical Inc. has a market cap of $11.57B, which represents its share price of $60.31 multiplied by its outstanding shares number of 191.78M. As a large-cap company, BMRN's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
BMRN 61.93 +1.62(2.69%)
Will BMRN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMRN
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
Other News for BMRN
BMRN Makes Bullish Cross Above Critical Moving Average
UBS Updates Its Analyst Rating and Target Price for BMRN | BMRN Stock News
UBS Adjusts Price Target for BioMarin (BMRN) to $114
BioMarin price target raised by $1 at UBS
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401